1. Home
  2. LGN vs ICUI Comparison

LGN vs ICUI Comparison

Compare LGN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGN

Legence Corp.

N/A

Current Price

$73.81

Market Cap

3.6B

Sector

N/A

ML Signal

N/A

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$129.91

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGN
ICUI
Founded
1963
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.9B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
LGN
ICUI
Price
$73.81
$129.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
4
Target Price
$54.43
$182.25
AVG Volume (30 Days)
2.0M
229.1K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.62
EPS
N/A
0.03
Revenue
N/A
$2,231,262,000.00
Revenue This Year
$53.66
N/A
Revenue Next Year
$11.99
$4.46
P/E Ratio
N/A
$4,201.67
Revenue Growth
N/A
N/A
52 Week Low
$28.31
$107.02
52 Week High
$70.35
$160.29

Technical Indicators

Market Signals
Indicator
LGN
ICUI
Relative Strength Index (RSI) 75.38 51.45
Support Level $42.97 $121.48
Resistance Level N/A $133.62
Average True Range (ATR) 3.47 4.24
MACD 1.51 1.15
Stochastic Oscillator 95.39 89.18

Price Performance

Historical Comparison
LGN
ICUI

About LGN Legence Corp.

Legence Corp is a provider of engineering, installation and maintenance services for mission-critical systems in buildings. It focuses on high-growth sectors that have technically demanding buildings, including technology, life sciences, healthcare and education. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting and building controls in existing facilities to make them more energy efficient and sustainable.

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

Share on Social Networks: